Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsOskarsdottir, Alma R
Gudmundsdottir, Brynja R
Jensdottir, Hulda M
Onundarson, Pall T
MetadataShow full item record
CitationOskarsdottir AR, Gudmundsdottir BR, Jensdottir HM, Flygenring B, Palsson R, Onundarson PT. Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study. Blood. 2021;137(20):2745-2755. doi:10.1182/blood.2020008698
AbstractDuring warfarin management, variability in prothrombin time-based international normalized ratio (PT-INR) is caused, in part, by clinically inconsequential fluctuations in factor VII (FVII). The new factor II and X (Fiix)-prothrombin time (Fiix-PT) and Fiix-normalized ratio (Fiix-NR), unlike PT-INR, are only affected by reduced FII and FX. We assessed the incidence of thromboembolism (TE) and major bleeding (MB) in all 2667 patients on maintenance-phase warfarin managed at our anticoagulation management service during 30 months; 12 months prior to and 18 months after replacing PT-INR monitoring with Fiix-NR monitoring. Months 13 to 18 were predefined as transitional months. Using 2-segmented regression, a breakpoint in the monthly incidence of TE became evident 6 months after test replacement, that was followed by a 56% reduction in incidence (from 2.82% to 1.23% per patient-year; P = .019). Three-segmented regression did not find any significant trend in TE incidence (slope, +0.03) prior to test replacement; however, during months 13 to 18 and 19 to 30, the incidence of TE decreased gradually (slope, -0.12; R2 = 0.20; P = .007). The incidence of MB (2.79% per patient-year) did not differ. Incidence comparison during the 12-month Fiix and PT periods confirmed a statistically significant reduction (55-62%) in TE. Fiix monitoring reduced testing, dose adjustments, and normalized ratio variability and prolonged testing intervals and time in range. We conclude that ignoring FVII during Fiix-NR monitoring in real-world practice stabilizes the anticoagulant effect of warfarin and associates with a major reduction in TEs without increasing bleeding.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
Rights© 2021 by The American Society of Hematology.
- During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.
- Authors: Jonsson PI, Letertre L, Juliusson SJ, Gudmundsdottir BR, Francis CW, Onundarson PT
- Issue date: 2017 Jan
- Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.
- Authors: Oskarsdóttir AR, Gudmundsdottir BR, Indridason OS, Lund SH, Arnar DO, Bjornsson ES, Magnusson MK, Jensdottir HM, Vidarsson B, Francis CW, Onundarson PT
- Issue date: 2017 May
- Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial.
- Authors: Onundarson PT, Francis CW, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, Juliusson SJ, Jensdottir HM, Vidarsson B, Gunnarsson PS, Lund SH, Gudmundsdottir BR
- Issue date: 2015 Jun
- The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin.
- Authors: Onundarson PT, Gudmundsdottir BR
- Issue date: 2019 Nov
- Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin.
- Authors: Onundarson PT, Arnar DO, Lund SH, Gudmundsdottir BR, Francis CW, Indridason OS
- Issue date: 2016 May